Latest News
Alvotech and Lotus agree licensing deal for two biosimilar candidates
21 August 2026 - Global biotechnology company Alvotech SA (NASDAQ: ALVO; STO: ALVO-SDB), which develops and manufactures biosimilar medicines, said on Friday it has signed a strategic licensing and commercialisation agreement with Lotus Pharmaceutica...
Genetic Analysis launches microbiome test at Centre for Digestive Diseases in Sydney
21 August 2026 - Genetic Analysis AS (Spotlight Stock Market: GEAN), a Norwegian microbiome diagnostics company, on Friday announced the launch of its technology at the Centre for Digestive Diseases in Sydney, a specialist gastroenterology centre off...
Leads Biolabs NDA for Opamtistomig accepted by China's CDE
21 August 2026 - China-based biotechnology company Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) said on Friday that the Centre for Drug Evaluation of the National Medical Products Administration has accepted its New Drug Application for Opamtistomig (...
Ipsen completes Kartos Therapeutics acquisition, strengthening late-stage oncology pipeline
21 August 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Friday that it has completed the acquisition of Kartos Therapeutics, adding the clinical-stage biopharmaceutical company's late-stage MDM2 inhi...
Nuvation Bio's safusidenib granted FDA Fast Track Designation for IDH1-mutant glioma treatment
21 August 2026 - Global oncology company Nuvation Bio Inc (NYSE:NUVB) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the company's investigational, oral, brain-penetrant s...